Overview

Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, non-comparative efficacy and safety study of Capecitabine and Mitomycin C as first-line treatment in patients with previously untreated metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Croatian Cooperative Group for Clinical Research in Oncology
Collaborator:
Roche Pharma AG
Treatments:
Capecitabine
Mitomycin
Mitomycins